CNS Pharmaceuticals, Inc.
Moat Score — CNS Pharmaceuticals, Inc.
Total Moat Score
3 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Berubicin holds Orphan Drug and Fast Track designations but no composition patent; TPI 287 has licensed patent protection to 2028 across four markets, but neither asset has a clear path to approval after CNS-201's failed primary endpoint. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | Pre-revenue clinical-stage company reliant on CROs for trial execution with no manufacturing or cost-structure advantage versus peers or large pharma. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | No approved products and no revenue; pricing power is entirely hypothetical and contingent on future approval that is not currently being pursued in-house. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | No network effects exist in a single/dual-asset clinical biotech business model; value is tied to clinical data and licensing deals, not user or provider networks. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Exclusive licensing terms with Cortice Biosciences for TPI 287 create modest counterparty lock-in, but there are no customer switching costs given the absence of any marketed product. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | An 8-employee company with ~$7.2 million in cash has no scale advantage and is explicitly outmatched by larger asset acquirers (Roivant, Ligand, Fortress) and big pharma competitors named in its own 10-K. |